ID   SK-MEL-28-VR
AC   CVCL_AP99
DR   cancercelllines; CVCL_AP99
DR   Wikidata; Q54954017
RX   PubMed=26497853;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf; PLX4032).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1773; CDK4; Simple; p.Arg24Cys (c.70C>T); ClinVar=VCV000016928; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Pro753Ser (c.2257C>T); ClinVar=VCV000376081; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr167Ala (c.499A>G); ClinVar=VCV001686107; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.-57A>C (c.161A>C) (A161C); ClinVar=VCV000242210; Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu145Arg (c.434T>G); ClinVar=VCV001027110; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Skin; UBERON=UBERON_0002097.
CC   Cell type: Melanocyte of skin; CL=CL_1000458.
DI   NCIt; C3510; Cutaneous melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0526 ! SK-MEL-28
SX   Male
AG   51Y
CA   Cancer cell line
DT   Created: 02-05-16; Last updated: 05-10-23; Version: 16
//
RX   PubMed=26497853; DOI=10.18632/oncotarget.5755;
RA   Fofaria N.M., Frederick D.T., Sullivan R.J., Flaherty K.T.,
RA   Srivastava S.K.;
RT   "Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors
RT   alone and in combination with MEK1/2 inhibitors in melanoma.";
RL   Oncotarget 6:40535-40556(2015).
//